CR20210310A - Anticuerpos antiperiostina y usos de estos - Google Patents

Anticuerpos antiperiostina y usos de estos

Info

Publication number
CR20210310A
CR20210310A CR20210310A CR20210310A CR20210310A CR 20210310 A CR20210310 A CR 20210310A CR 20210310 A CR20210310 A CR 20210310A CR 20210310 A CR20210310 A CR 20210310A CR 20210310 A CR20210310 A CR 20210310A
Authority
CR
Costa Rica
Prior art keywords
periostin antibodies
periostin
antibodies
block
function
Prior art date
Application number
CR20210310A
Other languages
English (en)
Inventor
Joanne Hulme
Arif Jetha
Johan Fransson
Aj Robert Mcgray
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of CR20210310A publication Critical patent/CR20210310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen en la presente anticuerpos que bloquean la función de la periostina. También se describen en la presente sus usos para tratar el cáncer y modificar las propiedades inmunitarias de los tumores.
CR20210310A 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos CR20210310A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779996P 2018-12-14 2018-12-14
US201962899075P 2019-09-11 2019-09-11
PCT/IB2019/001307 WO2020121059A1 (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20210310A true CR20210310A (es) 2021-11-24

Family

ID=71075443

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210310A CR20210310A (es) 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos

Country Status (22)

Country Link
US (1) US20220010003A1 (es)
EP (1) EP3894439A4 (es)
JP (2) JP2022513228A (es)
KR (1) KR20210108972A (es)
CN (1) CN113631571B (es)
AU (1) AU2019395887B2 (es)
BR (1) BR112021010634A2 (es)
CA (1) CA3120059A1 (es)
CL (1) CL2021001297A1 (es)
CO (1) CO2021007444A2 (es)
CR (1) CR20210310A (es)
DO (1) DOP2021000113A (es)
EC (1) ECSP21043288A (es)
IL (1) IL283890B2 (es)
JO (1) JOP20210144A1 (es)
MA (1) MA54472A (es)
MX (1) MX2021007043A (es)
PE (1) PE20211962A1 (es)
PH (1) PH12021551352A1 (es)
SA (1) SA521422250B1 (es)
SG (1) SG11202103849TA (es)
WO (1) WO2020121059A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4028056A4 (en) * 2019-09-11 2023-10-11 Boehringer Ingelheim IO Canada Inc. METHODS OF TREATING CANCER USING PD-1 AXIS INHIBITORS AND ANTI-PERIOSTIN ANTIBODIES
EP4403569A4 (en) * 2021-09-13 2025-10-29 Shenyang Eye Industry Tech Institute Ltd Humanized Monoclonal Antibody Against Periostin, Method of Preparation Thereof and Its Use
KR20240038198A (ko) 2022-09-15 2024-03-25 한남대학교 산학협력단 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2007096142A2 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20140363832A1 (en) * 2011-09-15 2014-12-11 National University Corporation Nagoya University Molecular marker for the early detection of malignant pleural mesothelioma and the methods of its expression analysis using blood and pleural effusion samples
WO2014136910A1 (ja) * 2013-03-08 2014-09-12 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
UA126146C2 (uk) * 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Терапевтичне антитіло до cd47

Also Published As

Publication number Publication date
CO2021007444A2 (es) 2021-09-30
CN113631571A (zh) 2021-11-09
WO2020121059A1 (en) 2020-06-18
ECSP21043288A (es) 2021-09-30
KR20210108972A (ko) 2021-09-03
DOP2021000113A (es) 2021-09-30
CL2021001297A1 (es) 2022-01-07
AU2019395887B2 (en) 2026-01-29
PH12021551352A1 (en) 2022-05-11
IL283890B1 (en) 2025-07-01
MX2021007043A (es) 2021-08-11
CA3120059A1 (en) 2020-06-18
IL283890A (en) 2021-07-29
IL283890B2 (en) 2025-11-01
JP2023139243A (ja) 2023-10-03
PE20211962A1 (es) 2021-10-04
US20220010003A1 (en) 2022-01-13
EP3894439A4 (en) 2022-11-30
MA54472A (fr) 2022-03-23
BR112021010634A2 (pt) 2021-11-16
JP2022513228A (ja) 2022-02-07
CN113631571B (zh) 2025-07-01
JP7681069B2 (ja) 2025-05-21
AU2019395887A1 (en) 2021-05-20
SA521422250B1 (ar) 2023-12-21
JOP20210144A1 (ar) 2023-01-30
EP3894439A1 (en) 2021-10-20
SG11202103849TA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
MX2021012134A (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2025000260A (es) Proteina de union al antigeno anti-steap1
EP3964527A3 (en) Combination therapy for cancer
MX2021015495A (es) Composiciones y métodos para tratar cáncer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12021551352A1 (en) Anti-periostin antibodies and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
WO2020186111A3 (en) Vista-binding antibodies and uses thereof
EA202191605A1 (ru) Антитела к периостину и их применение
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
WO2018148180A3 (en) Materials and methods for identifying and treating cancer patients
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها